Clinical Trial

Tetravalent Dengue Vaccine Candidate

Study Description

Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults

The purpose of this study is to assess the neutralizing antibody response against each dengue serotype post-vaccination.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Biological - Takeda's Tetravalent Dengue Vaccine Candidate (TDV)

Tetravalent Dengue Vaccine (TDV) subcutaneous injection

Additional Information

Official Study Title

An Open-Label, Phase 2 Trial to Investigate the Humoral and Cell-Mediated Immune Responses and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Flavivirus-Naïve and Dengue-Immune Healthy Adults

Clinical Trial ID

NCT03746015

ParticipAid ID

b4xW6b